vs

Side-by-side financial comparison of Ouster, Inc. (OUST) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Ouster, Inc. is the larger business by last-quarter revenue ($62.2M vs $35.5M, roughly 1.7× RECURSION PHARMACEUTICALS, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 106.6%). Ouster, Inc. produced more free cash flow last quarter ($-37.2M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 54.8%).

Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

OUST vs RXRX — Head-to-Head

Bigger by revenue
OUST
OUST
1.7× larger
OUST
$62.2M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+575.1% gap
RXRX
681.7%
106.6%
OUST
More free cash flow
OUST
OUST
$10.1M more FCF
OUST
$-37.2M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
54.8%
OUST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OUST
OUST
RXRX
RXRX
Revenue
$62.2M
$35.5M
Net Profit
$-108.1M
Gross Margin
60.2%
59.8%
Operating Margin
1.5%
-304.8%
Net Margin
-304.2%
Revenue YoY
106.6%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.10
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OUST
OUST
RXRX
RXRX
Q4 25
$62.2M
$35.5M
Q3 25
$39.5M
$5.2M
Q2 25
$35.0M
$19.2M
Q1 25
$32.6M
$14.7M
Q4 24
$30.1M
$4.5M
Q3 24
$28.1M
$26.1M
Q2 24
$27.0M
$14.4M
Q1 24
$25.9M
$13.8M
Net Profit
OUST
OUST
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-21.7M
$-162.3M
Q2 25
$-20.6M
$-171.9M
Q1 25
$-22.0M
$-202.5M
Q4 24
$-178.9M
Q3 24
$-25.6M
$-95.8M
Q2 24
$-23.9M
$-97.5M
Q1 24
$-23.8M
$-91.4M
Gross Margin
OUST
OUST
RXRX
RXRX
Q4 25
60.2%
59.8%
Q3 25
42.1%
-183.8%
Q2 25
45.2%
-4.9%
Q1 25
41.3%
-48.0%
Q4 24
43.8%
-181.4%
Q3 24
38.3%
53.7%
Q2 24
33.7%
36.2%
Q1 24
28.6%
19.1%
Operating Margin
OUST
OUST
RXRX
RXRX
Q4 25
1.5%
-304.8%
Q3 25
-61.4%
-3327.6%
Q2 25
-76.5%
-916.8%
Q1 25
-73.0%
-1297.9%
Q4 24
-85.1%
-4042.4%
Q3 24
-98.0%
-377.1%
Q2 24
-93.6%
-697.4%
Q1 24
-99.5%
-698.4%
Net Margin
OUST
OUST
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-55.0%
-3135.3%
Q2 25
-58.8%
-894.2%
Q1 25
-67.5%
-1373.3%
Q4 24
-3935.5%
Q3 24
-91.1%
-367.5%
Q2 24
-88.4%
-676.6%
Q1 24
-91.9%
-662.4%
EPS (diluted)
OUST
OUST
RXRX
RXRX
Q4 25
$0.10
$-0.17
Q3 25
$-0.37
$-0.36
Q2 25
$-0.38
$-0.41
Q1 25
$-0.42
$-0.50
Q4 24
$-0.46
$-0.56
Q3 24
$-0.54
$-0.34
Q2 24
$-0.53
$-0.40
Q1 24
$-0.55
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OUST
OUST
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$208.6M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$261.7M
$1.1B
Total Assets
$349.5M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OUST
OUST
RXRX
RXRX
Q4 25
$208.6M
$743.3M
Q3 25
$244.5M
$659.8M
Q2 25
$226.5M
$525.1M
Q1 25
$168.2M
$500.5M
Q4 24
$172.0M
$594.4M
Q3 24
$151.4M
$427.6M
Q2 24
$184.2M
$474.3M
Q1 24
$187.8M
$296.3M
Total Debt
OUST
OUST
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
OUST
OUST
RXRX
RXRX
Q4 25
$261.7M
$1.1B
Q3 25
$247.4M
$1.0B
Q2 25
$221.0M
$919.1M
Q1 25
$167.9M
$933.9M
Q4 24
$180.9M
$1.0B
Q3 24
$171.7M
$524.6M
Q2 24
$170.6M
$584.4M
Q1 24
$167.2M
$401.2M
Total Assets
OUST
OUST
RXRX
RXRX
Q4 25
$349.5M
$1.5B
Q3 25
$353.8M
$1.4B
Q2 25
$321.8M
$1.3B
Q1 25
$268.6M
$1.3B
Q4 24
$276.1M
$1.4B
Q3 24
$255.2M
$726.5M
Q2 24
$309.9M
$775.9M
Q1 24
$317.7M
$557.8M
Debt / Equity
OUST
OUST
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OUST
OUST
RXRX
RXRX
Operating Cash FlowLast quarter
$-15.4M
$-46.1M
Free Cash FlowOCF − Capex
$-37.2M
$-47.3M
FCF MarginFCF / Revenue
-59.8%
-133.1%
Capex IntensityCapex / Revenue
35.0%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-64.8M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OUST
OUST
RXRX
RXRX
Q4 25
$-15.4M
$-46.1M
Q3 25
$-18.3M
$-117.4M
Q2 25
$-1.3M
$-76.4M
Q1 25
$-4.9M
$-132.0M
Q4 24
$-2.6M
$-115.4M
Q3 24
$-3.8M
$-59.2M
Q2 24
$-21.6M
$-82.2M
Q1 24
$-5.7M
$-102.3M
Free Cash Flow
OUST
OUST
RXRX
RXRX
Q4 25
$-37.2M
$-47.3M
Q3 25
$-20.0M
$-117.6M
Q2 25
$-2.2M
$-79.6M
Q1 25
$-5.4M
$-133.8M
Q4 24
$-4.0M
$-116.7M
Q3 24
$-4.3M
$-63.8M
Q2 24
$-22.0M
$-83.4M
Q1 24
$-7.1M
$-109.0M
FCF Margin
OUST
OUST
RXRX
RXRX
Q4 25
-59.8%
-133.1%
Q3 25
-50.7%
-2272.5%
Q2 25
-6.3%
-413.9%
Q1 25
-16.6%
-907.4%
Q4 24
-13.3%
-2567.7%
Q3 24
-15.4%
-244.6%
Q2 24
-81.5%
-578.5%
Q1 24
-27.4%
-789.9%
Capex Intensity
OUST
OUST
RXRX
RXRX
Q4 25
35.0%
3.5%
Q3 25
4.3%
4.7%
Q2 25
2.5%
16.4%
Q1 25
1.7%
12.4%
Q4 24
4.8%
28.6%
Q3 24
2.0%
17.5%
Q2 24
1.3%
8.2%
Q1 24
5.3%
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons